{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:55:43Z","timestamp":1786550143720,"version":"build-2736575974"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:title>\n                    <jats:bold>ABSTRACT<\/jats:bold>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Nivolumab is a novel chemotherapy currently approved for the treatment of multiple metastatic malignancies. This class of therapy, known as immune checkpoint inhibitors, is notable for an autoimmune-related adverse event profile. Diarrhea and colitis are common gastrointestinal adverse events, however, upper gastrointestinal events are rarely reported. We present a case of nivolumab-associated esophagitis and gastritis that has yet to be reported in the published literature.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.14309\/crj.2017.57","type":"journal-article","created":{"date-parts":[[2017,4,13]],"date-time":"2017-04-13T15:55:41Z","timestamp":1492098941000},"page":"e57","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":73,"title":["Severe Esophagitis and Gastritis from Nivolumab Therapy"],"prefix":"10.14309","volume":"4","author":[{"given":"Justin","family":"Boike","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Dejulio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-57-20260710","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity.","volume":"26","author":"Keir","year":"2008","journal-title":"Annu Rev Immunol"},{"issue":"4","key":"R2-57-20260710","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkins lymphoma.","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"R3-57-20260710","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"R4-57-20260710","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck.","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"19","key":"R5-57-20260710","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma.","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"R6-57-20260710","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation.","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R7-57-20260710","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy.","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"R10-57-20260710","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R11-57-20260710","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors.","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"R12-57-20260710","first-page":"10","article-title":"Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma.","volume":"11","author":"Berman","year":"2010","journal-title":"Cancer Immun"},{"issue":"5","key":"R13-57-20260710","first-page":"560","article-title":"Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities.","volume":"4","author":"Villadolid","year":"2015","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"R14-57-20260710","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/1060028014528152","article-title":"Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient.","volume":"48","author":"Merrill","year":"2014","journal-title":"Ann Pharmacother"},{"issue":"17","key":"R15-57-20260710","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"}],"container-title":["ACG Case Reports Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/02075970-201704000-00057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:16:01Z","timestamp":1786547761000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02075970-201704000-00057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.14309\/crj.2017.57","relation":{},"ISSN":["2326-3253"],"issn-type":[{"value":"2326-3253","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}